Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Michigan Rogel Cancer Center
University of California, San Francisco
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
University of Colorado, Denver
Medical University of South Carolina
National Cancer Institute (NCI)
Incyte Corporation
Incyte Corporation
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Chicago
University of Chicago
Thomas Jefferson University
Bayer
Roswell Park Cancer Institute
University of Pittsburgh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Emory University
Northwestern University
University of Washington
Dana-Farber Cancer Institute
Rutgers, The State University of New Jersey
Bristol-Myers Squibb
Bristol-Myers Squibb
Nektar Therapeutics
Calithera Biosciences, Inc
Bristol-Myers Squibb
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Five Prime Therapeutics, Inc.
Incyte Corporation
Bristol-Myers Squibb
Washington University School of Medicine
National Cancer Institute (NCI)